Results 61 to 70 of about 3,972 (148)

Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Neuroendocrine neoplasms, which occur throughout the human body, as well as adrenocortical carcinoma and pheochromocytoma, which originate in the adrenal gland, are primarily classified as rare malignancies. Immunotherapy, including immune checkpoint inhibitors (ICIs), is generally not incorporated into the standard care protocols for these ...
Akihiro Ohmoto, Shunji Takahashi, Shigehisa Kitano   +2 more
wiley   +1 more source

ENTRECTINIB AND LAROTRECTINIB: CANCER-AGNOSTIC THERAPY

, 2022
reservednel 2021, l'AIFA ha approvato due nuovi farmaci, entrectinib e larotrectinib, che hanno l'innovazione di essere agnostici: danneggiano il tessuto tumorale indipendentemente dall'organo colpito, ma in base a mutazioni geniche che portano alla ...
BORDIGNON, ANGELA
core  

Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer [PDF]

PURPOSE: Neurotrophic tyrosine receptor kinase gene fusions are oncogenic drivers of various solid tumors. Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor approved for patients with TRK fusion cancer on the basis of single-
Brose, Marcia S., Bernard-Gauthier, Vadim, Westphalen, C. Benedikt, Kurtinecz, Milena, Drilon, Alexander, Aris, Virginie, Pennell, Nathan A., Guo, Helen, Pan, Xiaoyun, Subbiah, Vivek, Majdi, Abdelali, Brett, Neil R., Kehl, Kenneth L.   +12 more
core   +3 more sources

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.

, 2022
BACKGROUND: Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer.
Brega, Nicoletta, Gilbert, Jill, Raez, Luis E, Bauman, Jessica, Ho, Alan L, Brose, Marcia S, Grilley-Olson, Juneko E, Drilon, Alexander, Hong, David S, Patil, Tejas, Shen, Lin, Norenberg, Ricarda, Tahara, Makoto, Le, Xiuning, Johnson, Jennifer M, Baik, Christina, Dima, Laura, McDermott, Ray   +17 more
core   +1 more source

Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life

European Journal of Haematology, Volume 117, Issue 3, Page 548-555, September 2026.
ABSTRACT Background and Aims Retroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as the inferior vena cava (IVC).
Gaia Brunetti, Angelo Zarfati, Giorgio Persano, Giuseppe Maria Milano, Ida Russo, Gian Luigi Natali, Rita Alaggio, Alessandro Crocoli, Chiara Grimaldi   +8 more
wiley   +1 more source

A QbD-based stability-indicating RP-HPLC method for larotrectinib: degradation kinetics and integrated white, green, and blue analytical assessment

Journal of Applied Pharmaceutical Research
Background: Larotrectinib, a selective TRK inhibitor, received FDA approval on April 10, 2025, for treating solid tumors with NTRK gene fusions. Despite its therapeutic significance, no RP-HPLC method using a Quality-by-Design (QbD) framework has been ...
Syamala P. N. S, Sreedevi Adikay
doaj   +1 more source

Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement

Blood Advances, 2020
: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene.
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock   +14 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications Biology, 2020
Romel Somwar et al. find that cancer-causing NTRK gene fusions resistant to one form of inhibitor therapy can be resistant to other inhibitor types.
Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare   +14 more
doaj   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source